Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer

Medicine & Life Sciences

• N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine 100%
• Medullary Thyroid cancer 79%
• Therapeutics 10%
• Response Evaluation Criteria in Solid Tumors 6%
• Vascular Endothelial Growth Factor Receptor 5%
• Proto-Oncogenes 5%
• Calcitonin 5%
• Carcinoembryonic Antigen 5%
• Exanthema 4%
• Rare Diseases 4%
• ErbB Receptors 4%
• Serum 4%
• Nausea 4%
• Fatigue 4%
• Diarrhea 4%
• Disease Progression 3%
• Phosphotransferases 3%
• Research Personnel 3%
• Neoplasm Metastasis 2%
• Mutation 2%
• Neoplasms 1%